poor analysis. bio's are all about discounting the projected future. most small bio's DON'T have FDA approval and are selling at substantially higher caps. so should ISR. and ISR's cash and balance sheet are also pristine when compared to similarly situated bio's. save your ben graham intelligent investor analysis for when we are a half billion dollar company.